Recruiting Scleroderma Studies in Birmingham
Platform Clinical Study for Conquering Scleroderma
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung ...
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this...
About Scleroderma Clinical Trials in Birmingham
Scleroderma is an autoimmune connective tissue disease characterized by hardening and tightening of the skin and connective tissues. Systemic sclerosis can also affect internal organs including lungs, kidneys, and heart. Treatment is directed at specific symptoms and organ involvement.
There are currently 2 scleroderma clinical trials recruiting participants in Birmingham, MICHIGAN. These studies are seeking a combined 706 participants. Research is being sponsored by Scleroderma Research Foundation, Inc., AstraZeneca. Clinical trial participation is free and participants receive study-related medical care at no cost.
Scleroderma Clinical Trials in Birmingham — FAQ
Are there scleroderma clinical trials in Birmingham?
Yes, there are 2 scleroderma clinical trials currently recruiting in Birmingham, MICHIGAN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Birmingham?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.
Are clinical trials in Birmingham free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.
What scleroderma treatments are being tested?
The 2 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for scleroderma.
Data updated March 2, 2026 from ClinicalTrials.gov